( Excellent discussion of the challenges of conducting clinical trials in obesity ) Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP, SCALE Obesity and Prediabetes NN8022-1839 Study Group
Founds clinical team, using their broad toolkit of weight-loss medications, the use of MetabolicPrint, a proprietary metabolic health assessment to get to the root causes of your weight gain, will design a personalized treatment plan to target the biology your inability to lose weightto help you reach your health goals
Read our more blogs.
The average weight loss with Retatrutide exceeds 24%, meaning most users achieve cardiovascular risk reduction that would typically require multiple interventions